ArticleGene therapy2026
Mapping the global trends and hotspots of research on gene therapy and hair cell regeneration for hearing loss: a comprehensive data-mining-based study.
Article in Gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Hearing loss poses substantial global healthcare challenges, and conventional treatments remain inadequate for genetic etiologies, necessitating innovative approaches like gene therapy. This study presents the first comprehensive bibliometric analysis of hearing loss gene therapy to systematically map global trends, key contributors, and technological breakthroughs. We analyzed 2913 publications (1993-2025) from Web of Science, PubMed, and Scopus using advanced tools like CiteSpace, VOSviewer, and Bibliometrix. Metrics encompassed publication trends, country and institutional contributions, journal influence, author productivity, and keyword networks, with a focus on adeno-associated virus vectors and CRISPR/Cas9 technologies. Results indicate an exponential growth in publications, driven primarily by the USA and China, with the USA maintaining the highest citation impact. Harvard University, the University of Michigan, and Fudan University emerged as the top contributing institutions. Keyword analysis identified AAV-driven hair cell regeneration and CRISPR/Cas9-mediated mutation correction as the dominant research frontiers. While AAV-based studies currently dominate highly cited works, CRISPR/Cas9 applications have gained significant momentum since 2015. Furthermore, clinical trials targeting genes like OTOF reflect rapid translational progress, with round-window membrane injection emerging as the most prevalent and promising surgical delivery approach. Ultimately, this study highlights the dynamic evolution of auditory gene therapy, providing a roadmap that bridges foundational discoveries with clinical applications while underscoring the necessity of global collaboration.
Identifiers
42649271What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.